Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice

Bone Marrow Transplantation volume 43, pages 351–356 (2009)Cite this article

Abstract

The cytokine G-CSF stimulates myeloid progenitors and is routinely used to accelerate neutrophil recovery in the treatment of hematological malignancy and blood or marrow transplantation. Despite significant reductions in the frequency and duration of febrile neutropenia episodes, infections and the length of hospitalization, filgrastim has never been conclusively proven to produce a survival benefit in allogeneic HSCT and is considered a supportive measure. In this review, we analyze the conflicting evidence and appraise the utility of G-CSF in allogeneic HSCT. G-CSF administration after allogeneic HSCT needs to take into consideration the impact on immune reconstitution, risk of leukemic progression in patients with chromosome 7 abnormalities and the absence of proven benefit in patients receiving marrow or peripheral blood progenitors as the stem cell source.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985; 82: 1526–1530.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737–1746.

    CAS  PubMed  Google Scholar 

  3. Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC . Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996; 5: 491–501.

    Article  CAS  PubMed  Google Scholar 

  4. Filgrastim (Neuogen) Package Insert Amgen, Thousand Oaks, CA.

  5. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1996; 14: 1957–1960.

    Article  Google Scholar 

  6. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496–2502.

    CAS  PubMed  Google Scholar 

  7. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710–4718.

    CAS  PubMed  Google Scholar 

  8. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Dombret H . Granulocytic colony-stimulating factors in the management of patients with acute myeloid leukemia. Hematol Cell Ther 1996; 38: 231–240.

    Article  CAS  PubMed  Google Scholar 

  10. Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrozek K, Swann VL et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood 1996; 87: 1484–1494.

    CAS  PubMed  Google Scholar 

  11. Sultana TA, Harada H, Ito K, Tanaka H, Kyo T, Kimura A . Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol 2003; 121: 63–75.

    Article  CAS  PubMed  Google Scholar 

  12. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E . Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803–811.

    Article  PubMed  Google Scholar 

  13. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.

    Article  CAS  PubMed  Google Scholar 

  14. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  15. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009–1013.

    CAS  PubMed  Google Scholar 

  16. Bessho M, Hotta T, Ohyashiki K, Takahashi T, Mizoguchi H, Asano S et al. Multicenter prospective study of clonal complications in adult aplastic anemia patients following recombinant human granulocyte colony-stimulating factor (lenograstim) administration. Int J Hematol 2003; 77: 152–158.

    CAS  PubMed  Google Scholar 

  17. Konoplev S, Medeiros LJ, Lennon PA, Prajapati S, Kanungo A, Lin P . Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia. Cancer 2007; 110: 1520–1526.

    Article  PubMed  Google Scholar 

  18. Liu CZ, Persad R, Inghirami G, Sen F, Amorosi E, Goldenberg A et al. Transient atypical monocytosis mimic acute myelomonocytic leukemia in post-chemotherapy patients receiving G-CSF: report of two cases. Clin Lab Haematol 2004; 26: 359–362.

    Article  CAS  PubMed  Google Scholar 

  19. Nishimura M, Yamada T, Andoh T, Tao T, Emoto M, Ohji T et al. Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/G-CSF combined therapy. Int J Hematol 1998; 68: 203–211.

    Article  CAS  PubMed  Google Scholar 

  20. Yamazaki E, Kanamori H, Taguchi J, Harano H, Mohri H, Okubo T . The evidence of clonal evolution with monosomy 7 in aplastic anemia following granulocyte colony-stimulating factor using the polymerase chain reaction. Blood Cells Mol Dis 1997; 23: 213–218.

    Article  CAS  PubMed  Google Scholar 

  21. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002; 100: 786–790.

    Article  CAS  PubMed  Google Scholar 

  22. Kaito K, Kobayashi M, Katayama T, Masuoka H, Shimada T, Nishiwaki K et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 1998; 103: 297–303.

    Article  CAS  PubMed  Google Scholar 

  23. Imashuku S, Hibi S, Bessho F, Tsuchida M, Nakahata T, Miyazaki S et al. Detection of myelodysplastic syndrome/acute myeloid leukemia evolving from aplastic anemia in children, treated with recombinant human G-CSF. Haematologica 2003; 88: ECR31.

    PubMed  Google Scholar 

  24. Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109: 2794–2796.

    Article  CAS  PubMed  Google Scholar 

  25. White SM, Alarcon MH, Tweardy DJ . Inhibition of granulocyte colony-stimulating factor-mediated myeloid maturation by low level expression of the differentiation-defective class IV granulocyte colony-stimulating factor receptor isoform. Blood 2000; 95: 3335–3340.

    CAS  PubMed  Google Scholar 

  26. White SM, Ball ED, Ehmann WC, Rao AS, Tweardy DJ . Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia. Leukemia 1998; 12: 899–906.

    Article  CAS  PubMed  Google Scholar 

  27. Sloand EM, Yong AS, Ramkissoon S, Solomou E, Bruno TC, Kim S et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA 2006; 103: 14483–14488.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the MD Anderson Cancer Center experience. Transfusion 1999; 39: 555–560.

    Article  CAS  PubMed  Google Scholar 

  29. Anderlini P, Przepiorka D, Korbling M, Champlin R . Blood stem cell procurement: donor safety issues. Bone Marrow Transplant 1998; 21 (Suppl 3): S35–S39.

    PubMed  Google Scholar 

  30. Anderlini P, Przepiorka D, Lauppe J, Seong D, Giralt S, Champlin R et al. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 1997; 97: 485–487.

    Article  CAS  PubMed  Google Scholar 

  31. Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903–908.

    CAS  PubMed  Google Scholar 

  32. Rutella S, Zavala F, Danese S, Kared H, Leone G . Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 2005; 175: 7085–7091.

    Article  CAS  PubMed  Google Scholar 

  33. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702–3709.

    CAS  PubMed  Google Scholar 

  34. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13: 1461–1468.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415–419.

    Article  CAS  PubMed  Google Scholar 

  36. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100: 3128–3134.

    Article  CAS  PubMed  Google Scholar 

  37. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269–2274.

    CAS  PubMed  Google Scholar 

  38. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001; 97: 2514–2521.

    Article  CAS  PubMed  Google Scholar 

  39. Rondelli D, Raspadori D, Anasetti C, Bandini G, Re F, Arpinati M et al. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998; 22: 631–637.

    Article  CAS  PubMed  Google Scholar 

  40. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17: 101–109.

    CAS  PubMed  Google Scholar 

  41. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416–423.

    Article  CAS  PubMed  Google Scholar 

  42. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza Jr FR, Ringden O et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872–4880.

    Article  PubMed  Google Scholar 

  43. Khoury HJ, Loberiza Jr FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn JY et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107: 1712–1716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L . Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207–5215.

    Article  CAS  PubMed  Google Scholar 

  45. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D . The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003; 32: 771–775.

    Article  CAS  PubMed  Google Scholar 

  46. Rocha V, Wagner Jr JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342: 1846–1854.

    Article  CAS  PubMed  Google Scholar 

  47. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815–1822.

    Article  CAS  PubMed  Google Scholar 

  48. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611–1618.

    CAS  PubMed  Google Scholar 

  49. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205.

    Article  CAS  PubMed  Google Scholar 

  50. Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J et al. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 2007; 25: 343–351.

    Article  CAS  PubMed  Google Scholar 

  51. Lyman GH . Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005; 3: 557–571.

    Article  PubMed  Google Scholar 

  52. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F . Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol 1989; 73: 61–67.

    Article  CAS  PubMed  Google Scholar 

  53. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR . Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263–270.

    CAS  PubMed  Google Scholar 

  54. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C . Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484–2490.

    CAS  PubMed  Google Scholar 

  55. Rutella S, Rumi C, Sica S, Leone G . Recombinant human granulocyte colony-stimulating factor (rHuG-CSF): effects on lymphocyte phenotype and function. J Interferon Cytokine Res 1999; 19: 989–994.

    Article  CAS  PubMed  Google Scholar 

  56. Rutella S, Rumi C, Sica S, Leone G . Induction of T-cell mitogenic unresponsiveness by recombinant human granulocyte colony-stimulating factor (rHuG-CSF). Br J Cancer 2000; 82: 1610; author reply 1611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Zeng D, Dejbakhsh-Jones S, Strober S . Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453–463.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA

    M Battiwalla & P L McCarthy

Authors
  1. M Battiwalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P L McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Battiwalla.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Battiwalla, M., McCarthy, P. Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. Bone Marrow Transplant 43, 351–356 (2009). https://doi.org/10.1038/bmt.2008.443

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.443

Keywords

This article is cited by

Search

Advanced search

Quick links